Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Effects of captopril and enalapril on renal function in elderly patients with chronic heart failure.

Author information

Affiliations

  • 1. Department of Health Care for the Elderly, Selly Oak Hospital, West Midlands, UK.
      Authors
    • Haffner CA 1
    (1 author)

Postgraduate Medical Journal, 01 May 1995, 71(835):287-292
https://doi.org/10.1136/pgmj.71.835.287 PMID: 7596934 PMCID: PMC2398094

Free full text in Europe PMC

Abstract 

Objective

To compare the effects on renal function of captopril and enalapril in elderly patients with chronic heart failure.

Design

A multi-centre double-blind parallel-group comparison of the two angiotensin-converting enzyme (ACE) inhibitors, captopril (12.5 mg bid) and enalapril (2.5 mg bid).

Subjects

80 elderly patients with chronic heart failure (41 in the captopril group, 39 in the enalapril group).

Main outcome measures

The blood pressure and pulse rate response to the first dose of ACE inhibitor was assessed in all patients. Glomerular filtration rate (GFR) was measured radioisotopically by 99mTcDTPA or 51CrEDTA clearance after three and six months of each treatment. Subgroups were assessed for effective renal plasma flow (33 patients), exercise tolerance (25 patients) and by a symptom-oriented questionnaire (45 patients).

Results

No serious adverse effect on GFR was noticed. There was no significant difference between the two treatments in the mean baseline GFR or in changes from baseline at three and six months (captopril mean baseline GFR 49.6 ml min-1 1.76 m-2, enalapril 54.7 ml min-1 1.76 m-2; mean change (95% confidence interval) at three months captopril 12 ml min-1 (+3.0, +21.0), enalapril -2 ml min-1 (-13.0; +9.0); mean change at six months, captopril 3.7 ml min-1 (-6.7; +14.2), enalapril -6.0 ml min-1 (-21.0; +9.4). Significantly more patients given captopril had an improvement in GFR during the study period (26/31 compared with 20/31 enalapril-treated patients at three months, p = 0.0096, and 23/30 compared with 15/27 at six months, p = 0.021). There were no significant changes in effective renal plasma flow. Three patients treated with enalapril developed symptomatic hypotension within three days of starting treatment. Quality of life questionnaires revealed more gastrointestinal symptoms in the enalapril group (p = 0.039).

Conclusions

Captopril seems marginally preferable to enalapril in the treatment of chronic heart failure in elderly patients.

Free full text 

Logo of postmedjPostgraduate Medical JournalVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Postgrad Med J. 1995 May; 71(835): 287–292.
PMCID: PMC2398094
PMID: 7596934

Effects of captopril and enalapril on renal function in elderly patients with chronic heart failure.

C. A. Haffner, M. J. Kendall, A. D. Struthers, A. Bridges, and D. J. Stott
Author information Copyright and License information Disclaimer

Abstract

OBJECTIVE: To compare the effects on renal function of captopril and enalapril in elderly patients with chronic heart failure. DESIGN: A multi-centre double-blind parallel-group comparison of the two angiotensin-converting enzyme (ACE) inhibitors, captopril (12.5 mg bid) and enalapril (2.5 mg bid). SUBJECTS: 80 elderly patients with chronic heart failure (41 in the captopril group, 39 in the enalapril group). MAIN OUTCOME MEASURES: The blood pressure and pulse rate response to the first dose of ACE inhibitor was assessed in all patients. Glomerular filtration rate (GFR) was measured radioisotopically by 99mTcDTPA or 51CrEDTA clearance after three and six months of each treatment. Subgroups were assessed for effective renal plasma flow (33 patients), exercise tolerance (25 patients) and by a symptom-oriented questionnaire (45 patients). RESULTS: No serious adverse effect on GFR was noticed. There was no significant difference between the two treatments in the mean baseline GFR or in changes from baseline at three and six months (captopril mean baseline GFR 49.6 ml min-1 1.76 m-2, enalapril 54.7 ml min-1 1.76 m-2; mean change (95% confidence interval) at three months captopril 12 ml min-1 (+3.0, +21.0), enalapril -2 ml min-1 (-13.0; +9.0); mean change at six months, captopril 3.7 ml min-1 (-6.7; +14.2), enalapril -6.0 ml min-1 (-21.0; +9.4). Significantly more patients given captopril had an improvement in GFR during the study period (26/31 compared with 20/31 enalapril-treated patients at three months, p = 0.0096, and 23/30 compared with 15/27 at six months, p = 0.021). There were no significant changes in effective renal plasma flow. Three patients treated with enalapril developed symptomatic hypotension within three days of starting treatment. Quality of life questionnaires revealed more gastrointestinal symptoms in the enalapril group (p = 0.039). CONCLUSIONS: Captopril seems marginally preferable to enalapril in the treatment of chronic heart failure in elderly patients.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.2M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
 
icon of scanned page 287
287
icon of scanned page 288
288
icon of scanned page 289
289
icon of scanned page 290
290
icon of scanned page 291
291
icon of scanned page 292
292
 

Images in this article

p292-a
p292-a
on p.292
Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Giles T. Enalapril in the treatment of congestive heart failure. J Cardiovasc Pharmacol. 1990;15 (Suppl 3):S6–10. [Abstract] [Google Scholar]
  • Wheeldon NM, MacDonald TM, Flucker CJ, McKendrick AD, McDevitt DG, Struthers AD. Echocardiography in chronic heart failure in the community. Q J Med. 1993 Jan;86(1):17–23. [Abstract] [Google Scholar]
  • Cleland JG, Dargie HJ, Hodsman GP, Ball SG, Robertson JI, Morton JJ, East BW, Robertson I, Murray GD, Gillen G. Captopril in heart failure. A double blind controlled trial. Br Heart J. 1984 Nov;52(5):530–535. [Europe PMC free article] [Abstract] [Google Scholar]
  • Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep 3;327(10):669–677. [Abstract] [Google Scholar]
  • Murphy PJ, Van der Cammen T, Malone-Lee J. Captopril in elderly patients with heart failure. Br Med J (Clin Res Ed) 1986 Jul 26;293(6541):239–240. [Europe PMC free article] [Abstract] [Google Scholar]
  • Giles TD, Fisher MB, Rush JE. Lisinopril and captopril in the treatment of heart failure in older patients. Comparison of a long- and short-acting angiotensin-converting enzyme inhibitor. Am J Med. 1988 Sep 23;85(3B):44–47. [Abstract] [Google Scholar]
  • O'Neill CJ, Bowes SG, Sullens CM, Royston JP, Hunt WB, Denham MJ, Dobbs RJ, Dobbs SM. Evaluation of the safety of enalapril in the treatment of heart failure in the very old. Eur J Clin Pharmacol. 1988;35(2):143–150. [Abstract] [Google Scholar]
  • Packer M, Lee WH, Yushak M, Medina N. Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med. 1986 Oct 2;315(14):847–853. [Abstract] [Google Scholar]
  • Giles TD, Katz R, Sullivan JM, Wolfson P, Haugland M, Kirlin P, Powers E, Rich S, Hackshaw B, Chiaramida A, et al. Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. The Multicenter Lisinopril-Captopril Congestive Heart Failure Study Group. J Am Coll Cardiol. 1989 May;13(6):1240–1247. [Abstract] [Google Scholar]
  • Struthers AD. The clinical pharmacology of angiotensin converting enzyme inhibitors in chronic heart failure. Pharmacol Ther. 1992;53(2):187–197. [Abstract] [Google Scholar]
  • Waller DG, Keast CM, Fleming JS, Ackery DM. Measurement of glomerular filtration rate with technetium-99m DTPA: comparison of plasma clearance techniques. J Nucl Med. 1987 Mar;28(3):372–377. [Abstract] [Google Scholar]
  • Levine TB. Effect of angiotensin converting enzyme inhibition on renal function in the treatment of heart failure. Clin Ther. 1989 Jul-Aug;11(4):495–502. [Abstract] [Google Scholar]
  • Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991 Aug 1;325(5):303–310. [Abstract] [Google Scholar]
  • Packer M, Lee WH, Kessler PD, Medina N, Yushak M, Gottlieb SS. Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure. J Am Coll Cardiol. 1987 Oct;10(4):837–844. [Abstract] [Google Scholar]
  • MacFadyen RJ, Lees KR, Reid JL. Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study. Br Heart J. 1991 Sep;66(3):206–211. [Europe PMC free article] [Abstract] [Google Scholar]
  • McLay JS, McMurray J, Bridges A, Struthers AD. Practical issues when initiating captopril therapy in chronic heart failure. What is the appropriate dose and how long should patients be observed? Eur Heart J. 1992 Nov;13(11):1521–1527. [Abstract] [Google Scholar]
Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

Full text links 

Read article at publisher's site: https://doi.org/10.1136/pgmj.71.835.287

Read article for free, from open access legal sources, via Unpaywall: https://europepmc.org/articles/pmc2398094?pdf=renderUnpaywall

Citations & impact 

Impact metrics

7
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/45629178
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/45629178

Article citations

Go to all (7) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.